Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

Lancet

Volumn 356, Issue 9240, 2000, Pages 1493-1494

  Slobod, Karen S ^a,b   Taylor, Gregory H ^c   Sandlund, John T ^a,b   Furth, Priscilla ^c   Helton, Kathleen J ^a   Sixbey, John W ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; DOSE RESPONSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0034727395     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02879-8     Document Type: Article

References (5)

1. Primary central nervous system lymphoma
2. Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells
3. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity
4. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype
5. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy